Skip to main content
. Author manuscript; available in PMC: 2014 Feb 4.
Published in final edited form as: Clin Cancer Res. 2012 Jan 18;18(5):1227–1236. doi: 10.1158/1078-0432.CCR-11-2308

Table 2.

Pathology of MCC cases.

All Patients
n=60
PIK3CA Mutational Status MCPyV Status*

Positive n=7 Negative n=53 P value Positive n=38 Negative n=20 P value
No. (%) No. (%) No. (%) No. (%) No. (%)
Specimen size, cm <0.001 0.120
 Median 2.2 8.0 2.0 2.00 3.65
 Range 0.5-12.5 3.5-12.5 0.5-8.0 0.5-8.0 0.5-12.5

Specimen size 0.070 0.239
< 2cm 21 (35) 0 (0) 21 (40) 16 (42) 5 (25)
 2-12.5cm 31 (52) 6 (86) 25 (47) 18 (47) 13 (65)
 unknown 8 (13) 1 (14) 7 (13) 4 (11) 2 (10)

% Necrosis 0.053 0.010
 Median 0% 20% 0% 0% 5%
 Range 0-95% 0-60% 0-95% 0-95% 0-60%

Necrosis 0.095 0.004
 0% 37 (62) 2 (29) 35 (66) 29 (76) 7 (35)
 5-95% 23 (38) 5 (71) 18 (34) 9 (24) 13 (65)

Nucleoli visible 0.663 0.373
 Negative 42 (70) 6 (86) 36 (68) 28 (74) 12 (60)
 Positive 18 (30) 1 (14) 17 (32) 10 (26) 8 (40)

Spindle Shape 0.099 0.044
 Negative 55 (92) 5 (71) 50 (94) 37 (97) 16 (80)
 Positive/Pleomor. 5 (8) 2 (29) 3 (6) 1 (3) 4 (20)

Vascular Invasion 0.101 0.195
 Absent 31 (52) 1 (14) 30 (32) 23 (61) 7 (35)
 Present 8 (13) 2 (29) 6 (57) 4 (11) 4 (20)
 unknown 21 (35) 4 (57) 17 (11) 11 (29) 9 (45)
*

due to limited amount of tumor, we were unable to determine MCPyV status for two cases